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Abstract
The treatment of early stage breast cancer is evolving from
traditional breast conservation techniques, employing
conventionally fractionated whole breast irradiation, to techniques
in which partial breast irradiation is used in an accelerated
fractionation scheme. A growing body of evidence exists, including
favorable findings. Additional studies are under way that may
ultimately prove equivalence. The logic behind this approach is
reviewed, and the currently available data are presented to support
the current use of carefully applied partial breast irradiation
techniques in appropriately selected and informed patients.
Introduction
Over the past decade there has been growing interest in
decreasing the volumes of radiotherapeutic treatment post-
lumpectomy in breast conservation therapy (BCT). Historically,
we have demonstrated the need for post-lumpectomy radiation
to optimize local control. Currently, no subset of patients can
be successfully identified in whom radiotherapeutic treatment
can be eliminated when local control and breast preservation
are used as end-points [1]. More recently, we have
demonstrated the effectiveness of accelerated partial breast
irradiation (APBI) in maintaining excellent local control in select
subsets of patients [2]. The methods of APBI have evolved to
highly reproducible techniques with excellent quality assurance
[3]. Although continued study is important, APBI can be
offered as an option to patients who desire an alternative to
standard whole breast irradiation. To convince the reader, we
examine the history of BCT, the evolution of techniques
employed in APBI, the rationale supporting use of APBI, and
the growing data pool showing equivalence in properly
selected, properly treated patients. In addition, arguments
against APBI are examined and critiqued. In defending this
advance in treatment, appropriate selection criteria are
reviewed, published guidelines discussed, and ongoing
research reviewed.
Thoughtful consideration of the history and status of BCT
drives the need for better BCT options. Just as it was the
perception of a handful of institutions that led away from the
one size fits all, mastectomy for everyone dogma, it is a
questioning of the status quo of BCT that has led to a more
tailored approach. The concept that some patients could
undergo lumpectomy plus whole breast irradiation to maintain
an acceptable rate of local control and minimize morbidity is
evolving into further limitation in the volume treated in select
patients. Despite the demonstrated efficacy of BCT, many
women are still treated with mastectomy for a variety of
reasons, including time commitment, inconvenience, fear of
radiation, and treating physician bias [4,5]. Additionally, a
growing number of women are avoiding radiation post-
lumpectomy despite markedly reduced local control, probably
for similar reasons to those that lead to high mastectomy
rates [6]. Current Surveillance, Epidemiology, and End
Results (SEER) data from the USA demonstrate mastectomy
rates of 40–60% nationally, and lumpectomy alone rates of
46% in patients with ductal carcinoma in situ who are
potential BCT candidates [7]. If our goal is to minimize local
therapy on a more individualized basis while maintaining a
high breast conservation rate, then a need exists for another
treatment option such as APBI, which addresses patients’
and physicians’ concerns over treatment duration and side
effects. Shorter treatment courses with more focal side
effects may allay issues leading to high rates of mastectomy
and/or high rates of lumpectomy alone.
APBI techniques have evolved over time. In the USA
brachytherapy is the most commonly employed method,
whereas in Europe both brachytherapy and intraoperative
electron and photon beam techniques are used. Initially, the
US techniques were interstitial catheter based with low-dose
rate sources [8], but they have since evolved toward nearly
exclusively high-dose rate, image-guided techniques [3]. Data
exist that show outstanding target coverage and homogeneity
for these techniques [3]. Additionally, a balloon-based
interstitial catheter (MammoSite™, Proxima Therapeutics,
Alpharetta, Georgia, USA) has been cleared by the US Food
and Drug Administration and is now the most widely used
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form of APBI worldwide [9]. The evolution of the techniques
has led to high-quality implants with excellent target coverage
and reproducible homogeneity. The most common treatment
scheme is 34 Gy in 10 fractions given twice daily, over 5
treatment days to a volume covering the lumpectomy cavity
with a margin of 1–2 cm. More recently, US centers have
begun exploring three-dimensional external beam techniques
as a noninvasive option, despite the requirements for a larger
margin and a subsequent higher integral dose to surrounding
tissues [10]. The European experience with APBI has
included similar brachytherapy based methods but has
focused more on single, high-dose intraoperative treatments
with either photons or electrons, with the treatment delivered
at the time of lumpectomy [11,12]. Techniques performed at
the time of lumpectomy have been of less interest in the USA
because of lack of knowledge of final pathologic suitability for
treatment, unclear radiobiology, and lack of dosimetric quality
assurance.
Arguments
Regardless of the technique employed, an APBI approach
must maintain equivalence in results in critical end-points
including local control, breast preservation, cosmesis, and
patient acceptability. Local control and breast preservation
rates are obviously linked, and the supporting data for APBI
include pathologic studies, historical BCT studies that show
a lack of benefit elsewhere in the breast, and a growing single
institution database with promising results. First, we examine
the pathologic data supporting APBI.
Data from Holland and coworkers [13] have been used to
suggest the necessity of whole breast irradiation, but these
data are probably not valid in the modern era because of
large tumor size, high percentage of palpable lesions, and
suboptimal methodology, including simulated tumor
excisions, in those series. Studies that are more valid exist
that demonstrate a relatively small distance of extension of
disease from the main lesion to the pathologically identifiable
edge of the lesion. Careful specimen evaluation, as in the
studies by Imamura [14], Ohtake [15], and Goldstein [16]
and their coworkers, demonstrates tumor extension at
distances that are generally quite small and typically covered
by the margin of current APBI techniques. These modern
series include smaller tumors, more mammographically
detected tumors, and more realistic techniques for
determining tumor extent. The microscopic extent is typically
in the range of 5–15 mm, skip lesions are rare, and extent
appears to be age related.
A second argument in favor of APBI is the lack of evidence
demonstrating the effectiveness of whole breast irradiation in
preventing either local recurrence of the primary tumor
outside the tumor bed or the occurrence of future tumors
[1,17–20]. Data from both large randomized trials and single
institutional series show that ‘elsewhere recurrences’ occur
at essentially the same rate as new tumors in the contralateral
breast, suggesting that they in fact are new primary tumors
(Table 1) [1,17,18,21]. Because whole breast irradiation
does not affect new primary tumors, treating only the site of
most local recurrences seems logical.
Finally, giving further support to the use of APBI is the
growing body of data from multiple institutions that
demonstrates promising local control and cosmesis in
properly selected and properly treated patients (Table 2)
[2,23,31]. In a matched pair analysis, Vicini and coworkers
[2] recently demonstrated equivalence of APBI to whole
breast irradiation. Local recurrence, elsewhere failures,
cosmesis, and survival were all identical with a median follow
up of 5 years. More than 8 years of follow up in 62 patients
revealed no deterioration in outcomes (Vicini F, personal
communication). Additionally, the Radiation Therapy
Oncology Group study 95-17 [23] demonstrated the ability
of multiple institutions to effectively perform similar interstitial
catheter-based implants. The results to date with balloon-
based brachytherapy have been equivalent, with good
tolerance, cosmesis, and no local failures in the initial trial of
43 patients, now with a median follow up of 3 years.
Rebuttal of counter arguments
Opponents of APBI decry the treatment based on multiple
arguments, including survival concerns, selection bias, and
lack of adequate studies proving efficacy. Although these
concerns are natural for any new treatment paradigm, the
arguments appear to be overstated and in some cases
contradictory.
Table 1
Incidence of elsewhere failures from published randomized
trials
Follow up  Surgery  Surgery + 
Study (months) (%) radiation (%)
NSABP B06 [21] 144 2.7 3.8
Milan III [1] 39 1.5 0
Ontario [17] 91 3.6 1
Uppsala-Orebro [18] 65 3.7 –
NSABP, National Surgical Adjuvant Breast and Bowel Project.
Table 2
Results of published accelerated partial breast irradiation
studies with median follow up of 5 years
Local 
Number Follow  up  recurrence
Institution of patient (months) (%)
William Beaumont Hospital [2] 199 65 1.2
Ochsner Clinic [31] 45 75 2.0
National Institute of Oncology [22] 51 60 4.4108
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First, arguments concerning survival are directly contradictory
to those of selection bias and over-treatment of patients who
could be observed. The survival argument is based solely on
an as yet unpublished meta-analysis of multiple randomized
trials of lumpectomy with or without radiation [24]. Using a
meta-analysis as sole support for any argument is risky due to
methodological concerns. Using a meta-analysis with an arm
receiving no radiotherapy as an argument against APBI is
clearly flawed. Although absolute equivalence of APBI to
standard whole breast irradiation remains to be
demonstrated, it would be difficult to deny reasonable
efficacy, making a survival disadvantage highly unlikely.
The contradictory argument, that of over-selection of those
patients who do not actually need treatment, cannot be
supported by the literature. Even well selected
quadrantectomy trials show an advantage of radiotherapy [1].
The growing data pool supports treatment of the correct
subset of patients (Table 2). The importance of patient
selection and careful treatment delivery cannot be over-
emphasized. Three negative experiences with partial breast
irradiation exist in the literature and all support, by their failure,
the concept of careful selection and treatment quality
assurance [25,26,28]. The trials used different techniques,
including electron beam, iridium, and cesium needle
brachytherapy. The details are summarized in Table 3. The
studies share a lack of careful attention to patient selection
and/or technique, which would be considered substandard
by today’s guidelines. In general, if a patient is not a good
candidate for breast conservation because of their tumor
characteristics, then they are not candidates for APBI. In
addition, after selection, treatment must be performed with
care given to defining and treating the target adequately;
otherwise, both local control and toxicity results suffer.
Modern image-guided brachytherapy performed with high
dose rate remote afterloaders leads to well defined, highly
assured dose delivery.
Although additional study is warranted both to demonstrate
equivalence and further refine selection criteria, two
professional societies have published guidelines for APBI
with useful selection criteria (Table 4) [28,29]. The guidelines
are conservative and represent our current state of
knowledge of appropriate selection. Both societies
recommend enrollment in clinical trials if possible and
adequate informed consent in all cases. The process of
acquiring informed consent, as discussed by Arthur [30],
should include providing the prospective patient with
information regarding the status of the evidence supporting
APBI.
Conclusion
APBI is gaining acceptance in the management of early
breast cancers, and this is related to both improved delivery
techniques and from multiple single institutions reporting
positive experiences. Studies are ongoing and include an
upcoming phase III trial sponsored by the National Surgical
Adjuvant Breast and Bowel Project/Radiation Therapy
Table 3
Three trials reporting negative experiences with partial breast irradiation
Local recurrence
Trial Technique Selection criteria Quality assurance Whole breast Partial breast
Christies Hospital [25] Electron beam  No margin, stage,  No image guidance or  8% 34%
quadrant or histologic criteria verification of coverage
Guys Hospital [26] Cs137 MDR, 45 Gy Positive margins, nodes, EIC Dose, targeting, and volume issues NA 20%
London Regional [28] Ir192 HDR Positive nodes, EIC Small volume implants NA 16%
EIC, extensive intraductal component; HDR, high-dose rate; MDR, medium-dose rate.
Table 4
Published national professional society recommendations for accelerated partial breast irradiation
American Brachytherapy Society recommendations 1 [27] American Society of Breast Surgeons recommendations 2 [29]
Age (years) >45 >50
Diagnosis Unifocal, invasive ductal carcinoma Invasive ductal carcinoma or ductal carcinoma in situ
Tumor size <3 cm <2 cm
Surgical margin Negative microscopic surgical margins of excision Negative microscopic surgical margins of at least 2 mm in all directions
Node status N0 N0109
Oncology Group. Hopefully, this trial will offer a definitive
answer regarding equivalency and additional guidelines for
patient selection. In the 10 years before the data are mature,
physicians will need to examine the currently available data
and determine whether their patients are appropriate
candidates for APBI.
Competing interests
The author is a technical consultant for Proxima Therapeutics.
References
1. Veronesi U, Marubini E, Mariani L, Galimberti V, Luini A, Veronesi
P, Salvadori B, Zucali R: Radiotherapy after breast-conserving
surgery in small breast carcinoma: Long-term results of ran-
domized trial. Ann Oncol 2001, 12:997-1003.
2. Vicini FA, Kestin L, Chen P, Benitez P, Goldstein NS, Martinez A:
Limited-field radiation therapy in the management of early-
stage breast cancer. J Natl Cancer Inst 2003, 95:1205-1211.
3. Cuttino LW, Arthur DW, Todor DA, et al.:  CT- guided multi-
catheter insertion technique for partial breast brachytherapy
(PBB): Reliable target coverage and dose homogeneity.
Brachytherapy 2003, 2:41-68.
4. Hebert-Croteau N, Brisson J, Latreille J, Blanchette C, Deschenes
L: Compliance with consensus recommendation for the treat-
ment of early stage breast carcinoma elderly women. Cancer
1999, 85:1104-1113.
5. Athas WF, Adams-Cameron M, Hunt WC, Amir-Fazli A, Key CR:
Travel distance to radiation therapy and receipt of radiother-
apy following breast conserving surgery. J Natl Cancer Inst
2000, 92:269-271.
6. Nattinger AB, Hoffmann RG, Kneusel RT, Schapira MM: Relation
between appropriateness of primary therapy for early-stage
breast carcinoma and increased use of breast conserving
surgery. Lancet 2000, 356:1148-1153.
7. Baxter NN, Virnig BA, Durham SB, Tuttle TM: Trends in the treat-
ment of ductal carcinoma in situ of the breast. J Natl Cancer
Inst 2004, 96:443-448.
8. Vicini FA, Baglan KL, Kestin LL, Mitchell C, Chen PY, Frazier RC,
Edmundson G, Goldstein NS, Benitez P, Huang RR, et al.: Accel-
erated treatment of breast cancer. J Clin Oncol 2001,  19:
1993-2001.
9. Keisch M, Vicini F, Kuske RR, Hebert M, White J, Quiet C, Arthur
D, Scroggins T, Streeter O: Initial clinical experience with the
MammoSite breast brachytherapy applicator in women with
early stage breast cancer treated with breast conserving
therapy. Int J Radiat Oncol Biol Phys 2003, 55:289-293.
10. Baglan KL, Sharpe MB, Jaffray D, Frazier RC, Fayad J, Kestin LL,
Remouchamps V, Martinez AA, Wong J, Vicini FA: Accelerated
partial breast irradiation using 3D conformal radiation therapy
(3D-CRT). Int J Radiat Oncol Biol Phys 2003, 55:302-311.
11. Vaidya JS, Baum M, Tobias JS, D’Souza DP, Naidu SV, Morgan S,
Metaxas M, Harte KJ, Sliski AP, Thomson E: Targeted intra-oper-
ative radiotherapy (Targit): an innovative method of treatment
for early breast cancer. Ann Oncol 2001, 12:1075-1080.
12. Veronesi U, Orecchia R, Luini A, Gatti G, Intra M, Zurrida S, Ivaldi
G, Tosi G, Ciocca M, Tosoni A, et al.: A preliminary report of
intraoperative radiotherapy (IORT) in limited-stage breast
cancers that are conservatively treated. Eur J Cancer 2001, 37:
2178-2183.
13. Holland R, Veling SHJ, Mravunac M, Hendriks JH: Histologic
multifocality of Tis, T1-2 breast carcinomas: Implications for
clinical trials of breast-conserving surgery. Cancer 1985,
56:979-990.
14. Imamura H, Haga S, Shimizu T, Watanabe O, Kinoshita J, Nagumo
H, Kajiwara T, Aiba M: Relationship between morphological
and biological characteristics of intraductal components
accompanying invasive ductal breast carcinoma and patient
age. Breast Cancer Res Treat 2000, 62:177-184.
15. Ohtake T, Abe R, Kimijima I, Fukushima T, Tsuchiya A, Hoshi K,
Wakasa H: Intraductal extension of primary invasive breast
carcinoma treated by breast-conservative surgery. Cancer
1995, 76:32-45.
16. Goldstein NS, Kestin L, Vicini FV: Factors associated with ipsi-
lateral breast failure and distant metastasis in patients with
invasive breast carcinoma treated with breast conservation
therapy. Am J Clin Pathol 2003, 120:485-488.
17. Clark RM, McCulloch PB, Levine MN, Lipa M, Wilkinson RH,
Mahoney LJ, Basrur VR, Nair BD, McDermot RS, Wong CS, et al.:
Randomized clinical trial to assess the effectiveness of breast
irradiation following lumpectomy and axillary dissection for
node-negative breast cancer. J Natl Cancer Inst 1992, 84:683-
689.
18. Uppsala-Oreboro Breast Cancer Study Group: Sector resection
with or without postoperative radiotherapy stage I breast
cancer: a randomized trial. J Natl Cancer Inst 1990, 82:277-
282.
19. Fisher B, Anderson S: Conservative surgery for the manage-
ment of invasive and noninvasive carcinoma of the breast:
NSABP trials. World J Surg 1994, 18:63-69.
20. Holli K, Saaristo R, Isola J, Joensuu H, Hakama M: Lumpectomy
with or without postoperative radiotherapy for breast cancer
with favourable prognostic features: Results of a randomized
study. Br J Cancer 2001, 84:164-169.
21. Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher
ER, Jeong JH, Wolmark N: Twenty-year follow-up of a random-
ized trial comparing total mastectomy, lumpectomy, and
lumpectomy plus irradiation for the treatment of invasive
breast cancer. N Engl J Med 2002, 347:1233-1241.
22. Polgar C, Sulyok Z, Fodor J, Orosz Z, Major T, Takacsi-Nagy Z,
Mangel LC, Somogyi A, Kasler M, Nemeth G: Sole brachyther-
apy of the tumor bed after conservative surgery for T1 breast
cancer: five-year results of a phase I-II study and initial find-
ings of a randomized phase III trial. J Surg Oncol 2002, 80:
121-128.
23. Kuske RR, Bolton JS: A Phase I/II Trail to Evaluate Brachytherapy
as the Sole Method of Radiation Therapy for Stage I and II Breast
Carcinoma. Radiation Therapy Oncology Group Publication no.
1055. Philadelphia, PA: Radiation Therapy Oncology Group;
1995.
24. Storme G, Van de Steene J, Vinh-Hung V, for the Open Meta-
Analysis Project; Oncologisch Centrum, AZ-VUB, Brussels,
Belgium:  Radiation after lumpectomy for breast cancer
improves survival: Lack of evidence was not lack of an effect
[abstract 332]. Proc Am Soc Clin Oncol 2003, 22:83.
25. Ribeiro GG, Magee B, Swindell R, Harris M, Banerjee SS: The
Christie Hospital breast conservation trial: an update at 8
years from inception. Clin Oncol (R Coll Radiol) 1993, 5:278-
283.
26. Fentiman IS, Deshame V, Tong D, Winter J, Mayles H, Chaudary
MA: Caesium (137) implant as sole radiation therapy for oper-
able breast cancer: a phase II trial. Radiother Oncol 2004, 71:
281-285.
27. Arthur DW, Vicini FA, Kuske RR, Wazer DE, Nag S; American
Brachytherapy Society: Accelerated partial breast irradiation:
an updated report from the American Brachytherapy Society.
Brachytherapy 2002, 1:184-190.
28. Perera F, Yu E, Engel J, Holliday R, Scott L, Chisela F, Venkatesan
V:  Patterns of breast reoccurrence in a pilot study of
Brachytherapy confined to the lumpectomy site for early
breast cancer with six years’ minimum follow up. Int J Radiat
Oncol Biol Phys 2003, 57:1239-1246.
29. American Society of Breast Surgeons: Consensus Statement for
Accelerated Partial Breast Irradiation from the American Society
of Breast Surgeons [http://www.breastsurgeons.org/officialstmts/
officialstmt3.shtml]
30. Arthur D: Accelerated partial breast irradiation: a change in
treatment paradigm for early breast cancer. J Surg Oncol
2003, 84:185-191.
31. King TA, Bolton JS, Kuske RR, Fuhrman GM, Scroggins TG, Jiang
XZ: Long-term results of wide-field brachytherapy as the sole
method of radiation therapy after segmental mastectomy for
Tis,1,2 breast cancer. Ann J Surg 2000, 180:299-304.
Available online http://breast-cancer-research.com/content/7/3/106